Introduction
Biologic therapies have fundamentally altered the natural history of inflammatory bowel disease (IBD), yet their downstream impact on the systemic causes of mortality remains incompletely characterized. [1] This study examines how the leading underlying causes of death in patients with IBD like cardiovascular disease, infection, and malignancy have shifted across sequential treatment eras in the United States.[2]
Aims & Methods
We queried the CDC WONDER Multiple Cause of Death database to identify adult decedents with IBD (Crohn's disease or ulcerative colitis; ICD-9: 555–558; ICD-10: K50–K52) listed as a contributing cause of death. Mortality trends were stratified by temporal exposure to evolving treatment eras: the Pre-Biologic Era (1990–1998), the Early Biologic Era (1999–2010), and the Widespread Biologic Era (divided into 2011–2020 and 2021–2025 to capture recent trends). The absolute and proportional distributions of underlying causes of death—cardiovascular (ICD I00–I99), infection (ICD A00–B99), and malignancy (ICD C00–D48) were compared across eras alongside sex-stratified mortality.
Results
A total of 27,655 IBD-associated deaths were identified (Pre-Biologic: n = 7,414; Early Biologic: n = 7,929; Widespread 2011–2020: n = 7,571; Widespread 2021–2026: n = 4,741). Females accounted for the majority of IBD-associated deaths consistently across all eras (55.9%–60.8%). Cardiovascular disease was the dominant underlying cause throughout all biologic eras, accounting for 59.6%, 62.1%, and 57.7% of deaths in the Early Biologic, Widespread 2011–2020, and Widespread 2021–2026 eras, respectively. Absolute cardiovascular deaths declined markedly by 41.8% between the two Widespread biologic periods. Infection-related mortality constituted 35.9%, 33.2%, and 35.7% across the same periods, demonstrating a 7.6% relative increase in the most recent era. Malignancy-related deaths, while the smallest category, rose proportionally from 4.5% to 6.6% between the Early and most recent Widespread eras (a 47% relative increase).
Conclusion
Despite the transformative impact of biologics on luminal disease control, cardiovascular disease remains the predominant contributor to IBD-associated mortality, underscoring a persistent and under-addressed systemic burden. The relative rise in malignancy-related deaths across successive biologic eras warrants heightened vigilance for immunosuppression-associated neoplasia. These findings support the urgent need for integrated cardio-gastroenterology care models and systematic oncologic surveillance in the aging IBD population.
References
1) Banerjee, R., Ali, R. A. R., Wei, S. C., & Adsul, S. (2020). Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries. Gut and liver, 14(6), 685–698. https://doi.org/10.5009/gnl19209
2) Follin-Arbelet, B., Cvancarova Småstuen, M., Hovde, Ø., Jelsness-Jørgensen, L. P., & Moum, B. (2023). Mortality in Patients with Inflammatory Bowel Disease: Results from 30 Years of Follow-up in a Norwegian Inception Cohort (the IBSEN study). Journal of Crohn's & colitis, 17(4), 497–503. https://doi.org/10.1093/ecco-jcc/jjac156